Paradigm Biopharma completes enrolment in pivotal Phase 3 osteoarthritis trial

Welcome to HotCopper’s latest Watchlist, where we’ve this week been joined by Paradigm Biopharmaceuticals (ASX:PAR) managing director Paul Rennie to talk about what’s next after the company just cracked another “major milestone” in what’s shaping up to be a clear transformational year for the drug developer.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The biotech has completed enrollment in its Phase 3 osteoarthritis trial, with more than 500 patients now starting on a new breakthrough treatment.

Mr Rennie this week told HotCopper that this announcement is “probably the most significant in Paradigm’s ten-year history. Just to draw the comparison to big pharma companies, it’s one of their major milestones.”

“This is the last big milestone before you go to the U.S. FDA for registration.”

You can watch the full PAR Watchlist interview in the browser above.

Join the discussion. See what HotCopper users are saying about Paradigm Biopharmaceuticals Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.